Poliovirus vaccine inactivated - Intravacc/Sinovac/WHO

Drug Profile

Poliovirus vaccine inactivated - Intravacc/Sinovac/WHO

Alternative Names: Inactivated poliovirus vaccine - Intravacc/Sinovac/WHO; Poliovirus inactivated vaccine - Intravacc/Sinovac/WHO; Sabin inactivated polio vaccine - Intravacc/Sinovac/WHO; Sabin IPV - Intravacc/Sinovac/WHO; sIPV - Intravacc/Sinovac/WHO

Latest Information Update: 15 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Intravacc; National Institute of Public Health and the Environment; World Health Organization
  • Developer Intravacc; National Institute for Public Health and the Environment; Sinovac Biotech
  • Class Viral vaccines; Viruses
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Poliomyelitis

Most Recent Events

  • 15 Sep 2017 Intravacc plans to obtain market approval for polio vaccine inactivated (Sabin-IPV) in January 2019
  • 01 Jun 2017 Sinovac Biotech completes a phase I/II trial in Poliomyelitis (Prevention, In adults, In infants, In children, In adolescents) in China (IM) (NCT02985320)
  • 28 Nov 2016 Phase-II clinical trials in Poliomyelitis (Prevention, In infants) in China (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top